Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Free Cash Flow (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Free Cash Flow for 14 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 1818.97% year-over-year to -$3.2 million, compared with a TTM value of -$6.2 million through Dec 2025, up 12.52%, and an annual FY2025 reading of -$2.9 million, up 73.78% over the prior year.
  • Free Cash Flow was -$3.2 million for Q4 2025 at Neuroone Medical Technologies, down from -$1.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $951635.0 in Q3 2022 and bottomed at -$3.8 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$2.2 million, with a median of -$2.5 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 146.1% in 2022, then crashed 1818.97% in 2025.
  • Year by year, Free Cash Flow stood at -$2.7 million in 2021, then fell by 27.85% to -$3.5 million in 2022, then fell by 9.78% to -$3.8 million in 2023, then surged by 104.77% to $183633.0 in 2024, then plummeted by 1818.97% to -$3.2 million in 2025.
  • Business Quant data shows Free Cash Flow for NMTC at -$3.2 million in Q4 2025, -$1.5 million in Q3 2025, and -$1.5 million in Q2 2025.